Nissay Asset Management Corp Repligen Corp Transaction History

Nissay Asset Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$120.0 - $182.95 $16,680 - $25,430	139 Added 2.3%	6,182 $779,000
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $17,078 - $20,842	100 Added 1.68%	6,043 $1.11 Million
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $25,802 - $41,889	226 Added 3.95%	5,943 $1.07 Million
Q3 2023 Nov 14, 2023	BUY	$138.78 - $176.51 $27,478 - $34,948	198 Added 3.59%	5,717 $909,000
Q2 2023 Aug 14, 2023	SELL	$138.42 - $180.31 $12,734 - $16,588	-92 Reduced 1.64%	5,519 $780,000
Q1 2023 May 15, 2023	SELL	$154.26 - $198.1 $31,777 - $40,808	-206 Reduced 3.54%	5,611 $944,000
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $944,797 - $1.28 Million	5,817 New	5,817 $984,000

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Nissay Asset Management Corp with notifications on news.